CoChat
Sign Up
Cited by 377

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Sp1 transcription factor: A long-standing target in cancer chemotherapy

Vizcaíno, Carolina, Mansilla, Sylvia, Portugal, José·2015·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2015.05.008
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2015.05.008

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 176

  1. Abdelrahim, 2006, Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation, J Natl Cancer Inst, 98, 855, 10.1093/jnci/djj232 · DOI
  2. Abdelrahim, 2005, Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins, Mol Pharmacol, 68, 317, 10.1124/mol.105.011825 · DOI
  3. Abdelrahim, 2004, Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells, Cancer Res, 64, 6740, 10.1158/0008-5472.CAN-04-0713 · DOI
  4. Albertini, 2006, Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy, Nucleic Acids Res, 34, 1721, 10.1093/nar/gkl063 · DOI
  5. Ammanamanchi, 2003, Acetylated Sp3 is a transcriptional activator, J Biol Chem, 278, 35775, 10.1074/jbc.M305961200 · DOI
  6. Azizkhan, 1993, Transcription from TATA-less promoters: dihydrofolate reductase as a model, Crit Rev Eukaryot Gene Expr, 3, 229
  7. Barceló, 2010, DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis, Biochemistry, 49, 10543, 10.1021/bi101398s · DOI
  8. Barceló, 2007, Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences, Nucleic Acids Res, 35, 2215, 10.1093/nar/gkm037 · DOI
  9. Basha, 2011, Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors, Gynecol Oncol, 122, 163, 10.1016/j.ygyno.2011.03.014 · DOI
  10. Bataller, 2008, Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells, Mol Cancer Ther, 7, 2988, 10.1158/1535-7163.MCT-08-0420 · DOI
  11. Bedolla, 2012, Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence, PLoS One, 7, 10.1371/journal.pone.0044917 · DOI
  12. Beishline, 2015, Sp1 and the ‘hallmarks of cancer’, FEBS J, 282, 224, 10.1111/febs.13148 · DOI
  13. Black, 1999, Growth/Cell cycle regulation of Sp1 phosphorylation, J Biol Chem, 274, 1207, 10.1074/jbc.274.3.1207 · DOI
  14. Botella, 2001, Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-β stimulation, J Biol Chem, 276, 34486, 10.1074/jbc.M011611200 · DOI
  15. Bretones, 2015, Myc and cell cycle control, Biochim Biophys Acta, 1849, 506, 10.1016/j.bbagrm.2014.03.013 · DOI · Paper page
  16. Bywater, 2013, Dysregulation of the basal RNA polymerase transcription apparatus in cancer, Nat Rev Cancer, 13, 299, 10.1038/nrc3496 · DOI
  17. Chadalapaka, 2008, Curcumin decreases specificity protein expression in bladder cancer cells, Cancer Res, 68, 5345, 10.1158/0008-5472.CAN-07-6805 · DOI
  18. Chadalapaka, 2013, Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors, Int J Cancer, 132, 795, 10.1002/ijc.27730 · DOI
  19. Chaires, 1990, Preferential binding of daunomycin to 5′ATCG and 5′ATGC sequences revealed by footprinting titration experiments, Biochemistry, 29, 6145, 10.1021/bi00478a006 · DOI
  20. Chaires, 1997, Structure-based design of a new bisintercalating anthracycline antibiotic, J Med Chem, 40, 261, 10.1021/jm9607414 · DOI
  21. Chiang, 1998, A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1–DNA complexes and associated gene expression, Biochemistry, 37, 3109, 10.1021/bi9721142 · DOI
  22. Chintharlapalli, 2011, Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins, Mol Carcinog, 50, 655, 10.1002/mc.20738 · DOI
  23. Chintharlapalli, 2011, Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors, BMC Cancer, 11, 371, 10.1186/1471-2407-11-371 · DOI
  24. Chintharlapalli, 2007, Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors, Cancer Res, 67, 2816, 10.1158/0008-5472.CAN-06-3735 · DOI
  25. Choi, 2014, Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer, Sci Rep, 4, 7162, 10.1038/srep07162 · DOI
  26. Chu, 2012, Transcriptional regulation by post-transcriptional modification—role of phosphorylation in Sp1 transcriptional activity, Gene, 508, 1, 10.1016/j.gene.2012.07.022 · DOI
  27. Colon, 2011, Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice, Invest New Drugs, 29, 41, 10.1007/s10637-009-9331-8 · DOI
  28. Courey, 1989, Synergistic activation by the glutamine-rich domains of human transcription factor Sp1, Cell, 59, 827, 10.1016/0092-8674(89)90606-5 · DOI
  29. Crijns, 2009, Survival-related profile, pathways, and transcription factors in ovarian cancer, PLoS Med, 6, e1000024, 10.1371/journal.pmed.1000024 · DOI
  30. Dalvai, 2013, Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter, Oncogene, 32, 5123, 10.1038/onc.2012.524 · DOI
  31. Deacon, 2012, Elevated Sp-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer, J Biol Chem, 287, 39967, 10.1074/jbc.M112.397042 · DOI
  32. Deniaud, 2009, Overexpression of transcription factor Sp1 leads to gene expression perturbations and cell cycle inhibition, PLoS One, 4, e7035, 10.1371/journal.pone.0007035 · DOI
  33. Deniaud, 2006, Overexpression of Sp1 transcription factor induces apoptosis, Oncogene, 25, 7096, 10.1038/sj.onc.1209696 · DOI
  34. D'Incalci, 2007, Modulation of gene transcription by natural products—a viable anticancer strategy, Curr Pharm Des, 13, 2744, 10.2174/138161207781757097 · DOI
  35. Doetzlhofer, 1999, Histone deacetylase 1 can repress transcription by binding to Sp1, Mol Cell Biol, 19, 5504, 10.1128/MCB.19.8.5504 · DOI
  36. Essafi-Benkhadir, 2009, Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness, PLoS One, 4, e4478, 10.1371/journal.pone.0004478 · DOI
  37. Estève, 2007, Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells, J Biol Chem, 282, 2615, 10.1074/jbc.M606203200 · DOI
  38. Fandos, 1999, GLUT1 glucose transporter gene transcription is repressed by Sp3. Evidence for a regulatory role of Sp3 during myogenesis, J Mol Biol, 294, 103, 10.1006/jmbi.1999.3216 · DOI
  39. Feng, 2000, Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-β, EMBO J, 19, 5178, 10.1093/emboj/19.19.5178 · DOI
  40. Fernández-Guizán, 2014, The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription, Chem Biol Interact, 219, 123, 10.1016/j.cbi.2014.05.019 · DOI
  41. Fitzgerald, 2014, The role of transcription factors in prostate cancer and potential for future RNA interference therapy, Expert Opin Ther Targets, 18, 633, 10.1517/14728222.2014.896904 · DOI
  42. Fojas-de-Borja, 2001, Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription, EMBO J, 20, 5737, 10.1093/emboj/20.20.5737 · DOI
  43. Frank, 2009, Targeting transcription factors for cancer therapy, IDrugs, 12, 29
  44. Frederick, 1990, Structural comparison of anticancer drug–DNA complexes: adriamycin and daunomycin, Biochemistry, 29, 2538, 10.1021/bi00462a016 · DOI
  45. Fulciniti, 2011, Significant biological role of Sp1 transactivation in multiple myeloma, Clin Cancer Res, 17, 6500, 10.1158/1078-0432.CCR-11-1036 · DOI
  46. Gajek, 2014, Pro-apoptotic activity of new analog of anthracyclines—WP631 in advanced ovarian cancer cell line, Toxicol In Vitro, 28, 273, 10.1016/j.tiv.2013.11.006 · DOI
  47. Gao, 2011, Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis, Cancer Res, 71, 5182, 10.1158/0008-5472.CAN-10-2016 · DOI
  48. Gilmour, 2014, A crucial role for the ubiquitously expressed transcription factor Sp1 at early stages of hematopoietic specification, Development, 141, 2391, 10.1242/dev.106054 · DOI
  49. Göllner, 2001, Impaired ossification in mice lacking the transcription factor Sp3, Mech Dev, 106, 77, 10.1016/S0925-4773(01)00420-8 · DOI
  50. Grohar, 2013, Prospects and challenges for the development of new therapies for Ewing sarcoma, Pharmacol Ther, 137, 216, 10.1016/j.pharmthera.2012.10.004 · DOI
  51. Guan, 2012, Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome, Int J Cancer, 130, 593, 10.1002/ijc.26049 · DOI
  52. Gullett, 2010, Cancer prevention with natural compounds, Semin Oncol, 37, 258, 10.1053/j.seminoncol.2010.06.014 · DOI
  53. Hagen, 1992, Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes, Nucleic Acids Res, 20, 5519, 10.1093/nar/20.21.5519 · DOI
  54. Hagiwara, 2009, Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine, Brain Res, 1301, 189, 10.1016/j.brainres.2009.09.010 · DOI
  55. He, 2006, Sp1 and Sp3 foci distribution throughout mitosis, J Cell Sci, 119, 1063, 10.1242/jcs.02829 · DOI
  56. Hennessy, 2009, Ovarian cancer, Lancet, 374, 1371, 10.1016/S0140-6736(09)61338-6 · DOI
  57. Honda, 2006, Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells, J Biol Chem, 281, 21433, 10.1074/jbc.M603767200 · DOI
  58. Hong, 2002, 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression, Carcinogenesis, 23, 1297, 10.1093/carcin/23.8.1297 · DOI
  59. Hsu, 2012, Sp1 expression regulates lung tumor progression, Oncogene, 31, 3973, 10.1038/onc.2011.568 · DOI
  60. Hurley, 2002, DNA and its associated processes as targets for cancer therapy, Nat Rev Cancer, 2, 188, 10.1038/nrc749 · DOI
  61. Ishibashi, 2000, Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities, Cancer Res, 60, 6531
  62. Jia, 2010, Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity, Cancer Res, 70, 1111, 10.1158/0008-5472.CAN-09-3282 · DOI
  63. Jia, 2007, Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A, Cancer Res, 67, 4878, 10.1158/0008-5472.CAN-06-3494 · DOI
  64. Jiang, 2004, A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer, Clin Exp Metastasis, 21, 755, 10.1007/s10585-005-1198-2 · DOI
  65. Jiang, 2008, Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma, Cancer Epidemiol Biomarkers Prev, 17, 1648, 10.1158/1055-9965.EPI-07-2791 · DOI
  66. Jutooru, 2010, Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a, Mol Pharmacol, 78, 226, 10.1124/mol.110.064451 · DOI
  67. Jutooru, 2010, Inhibition of NFκB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation, J Biol Chem, 285, 25332, 10.1074/jbc.M109.095240 · DOI
  68. Jutooru, 2010, Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth, Exp Cell Res, 316, 2174, 10.1016/j.yexcr.2010.04.027 · DOI
  69. Jutooru, 2014, Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents, Mol Cell Biol, 34, 2382, 10.1128/MCB.01602-13 · DOI
  70. Kadonaga, 1986, Promoter-specific activation of RNA polymerase II transcription by Sp1, Trends Biochem Sci, 11, 20, 10.1016/0968-0004(86)90226-4 · DOI
  71. Kennett, 1997, Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription, Nucleic Acids Res, 25, 3110, 10.1093/nar/25.15.3110 · DOI
  72. Kim, 2012, Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer, Oncogene, 31, 1034, 10.1038/onc.2011.296 · DOI
  73. Kim, 1999, In vivo transcription factor recruitment during thyroid hormone receptor-mediated activation, Proc Natl Acad Sci U S A, 96, 10092, 10.1073/pnas.96.18.10092 · DOI
  74. King, 2001, Hepatotoxicity of chemotherapy, Oncologist, 6, 162, 10.1634/theoncologist.6-2-162 · DOI
  75. Kong, 2010, Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer, Cancer Sci, 101, 1463, 10.1111/j.1349-7006.2010.01554.x · DOI
  76. Koutsodontis, 2004, Inhibition of p53-mediated transcriptional responses by mithramycin A, Oncogene, 23, 9190, 10.1038/sj.onc.1208141 · DOI
  77. Koutsodontis, 2002, The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter, Biochemistry, 41, 12771, 10.1021/bi026141q · DOI
  78. Krüger, 2007, Sp1/Sp3 compound heterozygous mice are not viable: impaired erythropoiesis and severe placental defects, Dev Dyn, 236, 2235, 10.1002/dvdy.21222 · DOI
  79. Lee, 2006, Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites, Mol Cancer Ther, 5, 2737, 10.1158/1535-7163.MCT-06-0426 · DOI
  80. Lee, 2013, Effects of chimeric decoy oligodeoxynucleotide in the regulation of transcription factors NF-kB and Sp1 in an animal model of atherosclerosis, Basic Clin Pharmacol Toxicol, 112, 236, 10.1111/bcpt.12029 · DOI
  81. Lee, 2014, Specificity protein 1 expression contributes to Bcl-w-induced aggressiveness in glioblastoma multiforme, Mol Cells, 37, 17, 10.14348/molcells.2014.2161 · DOI
  82. Lee, 2012, The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1, Int J Mol Med, 30, 21
  83. Lee, 2009, Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells, Proc Natl Acad Sci U S A, 106, 2353, 10.1073/pnas.0812801106 · DOI · Paper page
  84. Lemon, 2000, Orchestrated response: a symphony of transcription factors for gene control, Genes Dev, 14, 2551, 10.1101/gad.831000 · DOI
  85. Leng, 1998, Ultratight DNA binding of a new bisintercalating anthracycline antibiotic, Biochemistry, 37, 1743, 10.1021/bi9720742 · DOI
  86. Letovsky, 1989, Measurement of the binding of transcription factor Sp1 to a single GC box recognition sequence, Nucleic Acids Res, 17, 2639, 10.1093/nar/17.7.2639 · DOI
  87. Li, 2010, The role of Sp1 and Sp3 in normal and cancer cell biology, Ann Anat, 192, 275, 10.1016/j.aanat.2010.07.010 · DOI
  88. Li, 2014, JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3, Breast Cancer Res Treat, 147, 487, 10.1007/s10549-014-3083-7 · DOI
  89. Li, 2004, Gene regulation by Sp1 and Sp3, Biochem Cell Biol, 82, 460, 10.1139/o04-045 · DOI
  90. Li, 2014, Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis, Cell Death Differ, 21, 1493, 10.1038/cdd.2014.69 · DOI
  91. López-Soto, 2006, Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor, J Biol Chem, 281, 30419, 10.1074/jbc.M604868200 · DOI
  92. Lou, 2005, Down-regulation of overexpressed Sp1 protein in human fibrosarcoma cell lines inhibits tumor formation, Cancer Res, 65, 1007, 10.1158/0008-5472.1007.65.3 · DOI
  93. MacQuarrie, 2011, Genome-wide transcription factor binding: beyond direct target regulation, Trends Genet, 27, 141, 10.1016/j.tig.2011.01.001 · DOI
  94. Majello, 1995, Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins, Oncogene, 10, 1841
  95. Malek, 2012, Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer, PLoS One, 7, e35130, 10.1371/journal.pone.0035130 · DOI
  96. Manne, 2005, Recent advances in biomarkers for cancer diagnosis and treatment, Drug Discov Today, 10, 965, 10.1016/S1359-6446(05)03487-2 · DOI
  97. Mansilla, 2008, Sp1 transcription factor as a target for anthracyclines: effects on gene transcription, Biochimie, 90, 976, 10.1016/j.biochi.2007.12.008 · DOI
  98. Mansilla, 2004, Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes, Biochemistry, 43, 7584, 10.1021/bi036185e · DOI
  99. Mansilla, 2006, Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms, Cell Cycle, 5, 53, 10.4161/cc.5.1.2267 · DOI · Paper page
  100. Mansilla, 2006, Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53, Eur J Pharmacol, 540, 34, 10.1016/j.ejphar.2006.04.035 · DOI
  101. Mansilla, 2011, Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters, Biochim Biophys Acta, 1809, 327, 10.1016/j.bbagrm.2011.06.003 · DOI
  102. Mansilla, 2007, Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells, Biochem Pharmacol, 73, 934, 10.1016/j.bcp.2006.12.005 · DOI
  103. Marin, 1997, Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation, Cell, 89, 619, 10.1016/S0092-8674(00)80243-3 · DOI
  104. Martín, 1999, Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro, Nucleic Acids Res, 27, 3402, 10.1093/nar/27.17.3402 · DOI
  105. Mertens-Talcott, 2007, The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells, Cancer Res, 67, 11001, 10.1158/0008-5472.CAN-07-2416 · DOI
  106. Minotti, 2004, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol Rev, 56, 185, 10.1124/pr.56.2.6 · DOI
  107. Minuzzo, 2000, Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743, Proc Natl Acad Sci U S A, 97, 6780, 10.1073/pnas.97.12.6780 · DOI
  108. Miyata, 2014, Contribution of transcription factor, Sp1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma, Cancer Med, 3, 1159, 10.1002/cam4.301 · DOI
  109. Mobahat, 2014, Survivin as a preferential target for cancer therapy, Int J Mol Sci, 15, 2494, 10.3390/ijms15022494 · DOI
  110. Moorefield, 2006, Sp2 localizes to subnuclear foci associated with the nuclear matrix, Mol Biol Cell, 17, 1711, 10.1091/mbc.E05-11-1063 · DOI
  111. Mottet, 2009, HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism, Oncogene, 28, 243, 10.1038/onc.2008.371 · DOI
  112. Nair, 2013, Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors, Carcinogenesis, 34, 2870, 10.1093/carcin/bgt231 · DOI
  113. Nicolás, 2003, Transcriptional regulation of the human Sp1 gene promoter by the specificity protein (Sp) family members nuclear factor Y (NF-Y) and E2F, Biochem J, 371, 265, 10.1042/bj20021166 · DOI
  114. Nikulenkov, 2012, Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis, Cell Death Differ, 19, 1992, 10.1038/cdd.2012.89 · DOI
  115. Noé, 1998, Retinoblastoma protein associates with Sp1 and activates the hamster dihydrofolate reductase promoter, Oncogene, 16, 1931, 10.1038/sj.onc.1201718 · DOI
  116. Noratto, 2013, The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis, Mol Nutr Food Res, 57, 1638, 10.1002/mnfr.201200609 · DOI
  117. Núñez, 2012, A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis, J Med Chem, 55, 5813, 10.1021/jm300234t · DOI
  118. Oeggerli, 2012, Role of KCNMA1 in breast cancer, PLoS One, 7, e41664, 10.1371/journal.pone.0041664 · DOI
  119. O'Sullivan-Coyne, 2009, Curcumin induces apoptosis-independent death in oesophageal cancer cells, Br J Cancer, 101, 1585, 10.1038/sj.bjc.6605308 · DOI
  120. Papineni, 2009, Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met, Carcinogenesis, 30, 1193, 10.1093/carcin/bgp092 · DOI
  121. Park, 2014, The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer, Cancer Treat Rev, 40, 68, 10.1016/j.ctrv.2013.05.006 · DOI
  122. Piedrafita, 1997, Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation, Mol Cell Biol, 17, 6348, 10.1128/MCB.17.11.6348 · DOI
  123. Portugal, 2011, Promoter-specific transcriptional interference by DNA-binding drugs, Vol. 8, 45
  124. Portugal, 2001, Analysis of the effects of daunorubicin and WP631 on transcription, Curr Med Chem, 8, 1, 10.2174/0929867013373976 · DOI
  125. Previdi, 2010, Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts, Gynecol Oncol, 118, 182, 10.1016/j.ygyno.2010.03.020 · DOI
  126. Priebe, 2001, Exploiting anthracycline scaffold for designing DNA-targeting agents, Methods Enzymol, 340, 529, 10.1016/S0076-6879(01)40441-1 · DOI
  127. Pugh, 1990, Mechanism of transcriptional activation by Sp1: evidence for coactivators, Cell, 61, 1187, 10.1016/0092-8674(90)90683-6 · DOI
  128. Roeder, 2003, The eukaryotic transcriptional machinery: complexities and mechanisms unforeseen, Nat Med, 9, 1239, 10.1038/nm938 · DOI
  129. Safe, 2005, Sp transcription factor family and its role in cancer, Eur J Cancer, 41, 2438, 10.1016/j.ejca.2005.08.006 · DOI
  130. Safe, 2014, Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target, Expert Opin Ther Targets, 18, 759, 10.1517/14728222.2014.914173 · DOI
  131. Saha, 2015, Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin, Transl Res, 165, 558, 10.1016/j.trsl.2014.10.011 · DOI
  132. Sankpal, 2011, Targeting Sp1 transcription factors in prostate cancer therapy, Med Chem, 7, 518, 10.2174/157340611796799203 · DOI
  133. Sankpal, 2013, Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation, Cell Physiol Biochem, 32, 675, 10.1159/000354471 · DOI
  134. Sankpal, 2012, Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy, Curr Med Chem, 19, 3779, 10.2174/092986712801661077 · DOI
  135. Shaw, 2008, Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo, Int J Cancer, 122, 10.1002/ijc.23278 · DOI
  136. Sherr, 1999, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev, 13, 1501, 10.1101/gad.13.12.1501 · DOI · Paper page
  137. Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 65, 5, 10.3322/caac.21254 · DOI
  138. Sleiman, 2011, Mithramycin is a gene-selective Sp1 Inhibitor that identifies a biological intersection between cancer and neurodegeneration, J Neurosci, 31, 6858, 10.1523/JNEUROSCI.0710-11.2011 · DOI
  139. Snyder, 1991, 30, 4290
  140. Sorianello, 2012, The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells, Cardiovasc Res, 94, 38, 10.1093/cvr/cvs006 · DOI
  141. Sreevalsan, 2013, The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells, Mol Cancer Ther, 12, 2483, 10.1158/1535-7163.MCT-13-0486 · DOI
  142. Stevens, 2003, Chk2 activates E2F-1 in response to DNA damage, Nat Cell Biol, 5, 401, 10.1038/ncb974 · DOI
  143. Suske, 1999, The Sp-family of transcription factors, Gene, 238, 291, 10.1016/S0378-1119(99)00357-1 · DOI
  144. Sutphin, 2014, Anti-leukemic response of a NSAID, tolfenamic acid, Target Oncol, 9, 135, 10.1007/s11523-013-0274-9 · DOI
  145. Tapias, 2008, Regulation of Sp1 by cell cycle related proteins, Cell Cycle, 7, 2856, 10.4161/cc.7.18.6671 · DOI
  146. Terrados, 2012, Genome-wide localization and expression profiling establish Sp2 as a sequence-specific transcription factor regulating vitally important genes, Nucleic Acids Res, 40, 7844, 10.1093/nar/gks544 · DOI
  147. Tora, 2010, The TATA box regulates TATA-binding protein (TBP) dynamics in vivo, Trends Biochem Sci, 35, 309, 10.1016/j.tibs.2010.01.007 · DOI
  148. Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 · DOI
  149. Vaquero, 1998, Modulation of DNA–protein interactions in the P1 and P2 c-myc promoters by two intercalating drugs, Eur J Biochem, 251, 435, 10.1046/j.1432-1327.1998.2510435.x · DOI
  150. Vizcaíno, 2012, Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes, Biochem Pharmacol, 84, 1133, 10.1016/j.bcp.2012.08.003 · DOI
  151. Vizcaíno, 2014, Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue, PLoS One, 9, e104687, 10.1371/journal.pone.0104687 · DOI
  152. Wang, 2008, Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process, J Mol Biol, 380, 869, 10.1016/j.jmb.2008.05.043 · DOI
  153. Wang, 2008, Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models, Int J Oncol, 33, 161
  154. Wang, 2014, Identification of genes and candidate agents associated with pancreatic cancer, Tumour Biol, 35, 81, 10.1007/s13277-013-1009-3 · DOI
  155. Wang, 2007, Expression and prognostic value of transcriptional factor sp1 in breast cancer, Ai Zheng, 26, 996
  156. Wang, 2003, Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer, Clin Cancer Res, 9, 6371
  157. Wierstra, 2008, Sp1: emerging roles—beyond constitutive activation of TATA-less housekeeping genes, Biochem Biophys Res Commun, 372, 1, 10.1016/j.bbrc.2008.03.074 · DOI
  158. Wright, 1987, Prognostic factors in breast cancer: immunohistochemical staining for SP1 and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status, J Pathol, 153, 325, 10.1002/path.1711530406 · DOI
  159. Wu, 2005, Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity, J Biol Chem, 280, 9745, 10.1074/jbc.M409350200 · DOI
  160. Xu, 2014, Variation in Sp1 binding sites correlates with expression of survivin in breast cancer, Mol Med Rep, 10, 1395, 10.3892/mmr.2014.2371 · DOI
  161. Xu, 2007, Sp1 and Sp3 regulate basal transcription of the survivin gene, Biochem Biophys Res Commun, 356, 286, 10.1016/j.bbrc.2007.02.140 · DOI
  162. Yan, 2013, Drugging the undruggable: transcription therapy for cancer, Biochim Biophys Acta, 1835, 76
  163. Yang, 2014, The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis, Neoplasia, 16, 1059, 10.1016/j.neo.2014.09.011 · DOI
  164. Yang, 2014, Pin1-mediated Sp1 phosphorylation by CDK1 increases Sp1 stability and decreases its DNA-binding activity during mitosis, Nucleic Acids Res, 42, 13573, 10.1093/nar/gku1145 · DOI
  165. Yao, 2004, Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer, Clin Cancer Res, 10, 4109, 10.1158/1078-0432.CCR-03-0628 · DOI
  166. Yu, 2003, Stability of the Sp3–DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites, Nucleic Acids Res, 31, 5368, 10.1093/nar/gkg706 · DOI
  167. Yuan, 2007, Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer, Cancer, 110, 2682, 10.1002/cncr.23092 · DOI
  168. Zannetti, 2000, Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma, Cancer Res, 60, 1546
  169. Zhang, 2012, Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells, Cancer Res, 72, 4178, 10.1158/0008-5472.CAN-11-3983 · DOI
  170. Zhang, 2015, Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells, Toxicol Lett, 232, 481, 10.1016/j.toxlet.2014.11.028 · DOI
  171. Zhang, 2014, Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma, J Transl Med, 12, 222, 10.1186/s12967-014-0222-1 · DOI
  172. Zhang, 2005, Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis, World J Gastroenterol, 11, 2213, 10.3748/wjg.v11.i15.2213 · DOI
  173. Zhao, 2005, Sp1-like transcription factors are regulators of embryonic development in vertebrates, Dev Growth Differ, 47, 201, 10.1111/j.1440-169X.2005.00797.x · DOI
  174. Zhao, 2015, β-Elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKalpha signalling pathways in human lung cancer cells: the role of Sp1, J Cell Mol Med, 19, 630, 10.1111/jcmm.12476 · DOI
  175. Zhao, 2013, Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts, Oncol Rep, 30, 1782, 10.3892/or.2013.2627 · DOI
  176. Zhu, 2002, The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells, Oncogene, 21, 8477, 10.1038/sj.onc.1206030 · DOI

Cited by

Sorted by citations

Metadata

Authors
Vizcaíno, C., Mansilla, S., & Portugal, J.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2015-08
Volume
152
Pages
111-124
ISSN
0163-7258
DOI
10.1016/j.pharmthera.2015.05.008
Cited by
377
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
European Social Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review